WO1986007357A3 - Composes de cyclopentapyrazole et de tetrahydroindazole - Google Patents

Composes de cyclopentapyrazole et de tetrahydroindazole

Info

Publication number
WO1986007357A3
WO1986007357A3 PCT/US1986/001233 US8601233W WO8607357A3 WO 1986007357 A3 WO1986007357 A3 WO 1986007357A3 US 8601233 W US8601233 W US 8601233W WO 8607357 A3 WO8607357 A3 WO 8607357A3
Authority
WO
WIPO (PCT)
Prior art keywords
tetrahydro
phenyl
coom
acid
cyclopentapyrazolyl
Prior art date
Application number
PCT/US1986/001233
Other languages
English (en)
Other versions
WO1986007357A2 (fr
Inventor
Herman W. Smith
Original Assignee
The Upjohn Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Upjohn Company filed Critical The Upjohn Company
Publication of WO1986007357A2 publication Critical patent/WO1986007357A2/fr
Publication of WO1986007357A3 publication Critical patent/WO1986007357A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Definitions

  • This invention relates to novel cyclopentapyrazole and tetrahydroindazole compounds and to the use of those compounds as anti-asthmatic agents, antiinflammatory agents or intermediates.
  • the compounds of this invention are composed of a 1,3 substituted pyrazole ring additionally substituted at the four and five positions by a saturated cyclic ring of 5 or 6 carbon atoms.
  • INFORMATION DISCLOSURE M Nagakura et al., J. Med. Chem. 22: (No. 1), 48-52 (1979) describes 1-(2-)-aryl-4,5,6,7-tetrahydro-1H-indazole-5-carboxylic acid derivatives which demonstrated antiinflammatory activity in the carragenan edema test.
  • Tetrahydroindazoles having utility as intermediates and corrosion inhibitors are described in W. German 1,948,793.
  • N-Aryl-tetrahydroindazole derivatives having utility as anti- inflammatory agents are described in Japan 50095-262.
  • Dialkylamino-4,5,6,7-tetrahydroindazole derivatives having dopamine potentiating and prolactic secretion inhibiting activities are described in Belgium 877,330.
  • 4,5,6,7-Tetrahydro-1H (or 2H) indazole compounds having utility in treating Parkinsonism are described in U.S. 4,322,430.
  • alkyl of one to nine carbon atoms, inclusive are methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, and nonyl, and isomeric forms thereof.
  • Pharmaceutically acceptable salts of the compounds of Formula XXX wherein M 1 is hydrogen are those formed with any suitable inorganic or organic bases, such as those of alkali metals, for example, sodium and potasium; alkaline earth metals, for example, calcium and magnesium; light metals of Group IIIA, for example, aluminum; and organic amines.
  • Such salts are pharmacologically acceptable amine salts, i.e., amines which are accepted by mammals in an essentially non-toxic manner when administered to mammals in conjunction with the acid moiety of the invention.
  • Illustrative of the amines are those derived from primary, secondary, or tertiary amines.
  • Suitable amines are methylamine, dimethylamine, triethylamine, ethylamine, dibutylamine, triisopropylamine, N-methylhexylamine, decylamine, dodecylamine, allylamine, crotylamine, cyclopentylamine, dicyclohexylamine, benzylamine, dibenzylamine, ⁇ -phenylethylamine, ⁇ -phenylethylamine, ethylenediamine, diethylenetriamine, adamantylamines, and like aliphatic, cycloaliphatic, and araliphatic amines containing up to and including about 18 carbon atoms as well as heterocyclic amines, e.g., piperidine, morpholine, pyrrolidine, piperazine, and lower-alkyl derivatives thereof, e.g., 1-methylpiperidine, 4-ethylmorpholine, 1-isopropylpyr
  • Formula IX represents the geometrical isomer mixture.
  • Formulae X and XI represent the pure geometric isomers in the cis configuration and trans configuration, respectively.
  • Chart A describes the method by which novel compounds of this invention are prepared.
  • Charts B and C describe methods by which additional novel compounds of this invention are prepared from the final compound in Chart A.
  • Chart D herein describes the method by which intermediates in Chart A may be prepared.
  • Chart E herein describes the method by which additional novel compounds of this invention are prepared from intermediates in Chart A.
  • Dipolar cycloaddition of the nitrilamine derived from the formula III bromo-substituted hydrazone with the appropriate amine e.g., morpholino-cyclopentene or pyrrolidino-cyclopentene; morpholino-cyclohexene or pyrrol idino-cyclohexene
  • the appropriate amine e.g., morpholino-cyclopentene or pyrrolidino-cyclopentene; morpholino-cyclohexene or pyrrol idino-cyclohexene
  • the carboethoxy group of the formula V cyclopentapyrazole or tetrahydroindazole e.g., when R 1 is nitrophenyl, bromophenyl, or chlorophenyl
  • R 1 is nitrophenyl, bromophenyl, or chlorophenyl
  • the carbinol of formula VII is obtained by treatment with diborane.
  • Oxidation of the carbinols of formula VII are conveniently performed with activated manganese dioxide in toluene under azeotropic distillation conditions to provide the carboxaldehydes of formula
  • IX i.e., formulae X and XI, are conveniently separated on silica gel as the corresponding methyl esters (e.g., when n is 1 to 5 and M 1 is
  • the carboxaldehydes of formula VIII are converted to the compound of formula XVII by wittig reactions.
  • the compound of formula XIII is obtained by reduction of the compound of formula XVII.
  • Reduction of the vinyl group of formula XVII is conveniently performed by catalytic hydrogenation (e.g., palladium on carbon, platinum oxide catalysis) when substituents insensitive to reduction or hydrogenolysis are present (e.g., when R 1 is tolyl, trtfluoromethylphenyl, fluorophenyl, or acetamidophenyl).
  • Diborane reduction achieves the same objective when reduction-sensitive substituents are present (e.g., when R 1 is chlorophenyl, bromophenyl, or nitrophenyl).
  • Geometrical isomers are separated on silica gel or more easily on silica gel pretreated with silver nitrate.
  • the carboxaldehyde of formula VIII is converted to the compound of formula XXVII by reaction with alcohol (e.g., R 13 OH or R 12 OH) or glycol (e.g., HOCH 2 -C-CH 2 OH) in the presence of acid (e.g., t ⁇ luenesulfonic acid) neat in the case of lower-alkyl alcohols and with a solvent (e.g., toluene) in the case of glycols.
  • alcohol e.g., R 13 OH or R 12 OH
  • glycol e.g., HOCH 2 -C-CH 2 OH
  • acid e.g., t ⁇ luenesulfonic acid
  • solvent e.g., toluene
  • reduction of the vinyl group of the formula IX compound to the formula XII compound is conveniently performed by catalytic hydrogenation (e.g., palladium on carbon, platinum oxide catalysis) when substituents insensitive to reduction or hydrogenolysis are present (e.g., when R 1 is tolyl, trifluoromethylphe- nyl, fluorophenyl, or acetamidophenyl).
  • Diborane reduction achieves the same objective when reduction-sensitive substituents are present (e.g., when R 1 is chlorophenyl, bromophenyl, or nitrophenyl).
  • the catalytic hydrogenations are easily performed on either the esters of formula IX (e.g., when n is 1 to 5 and Mi is -CH 3 ) or the acids of formula IX (e.g., when n is 1 to 5 and Mi is -H).
  • Diborane reduction of vinyl substituents is best conducted on the esters of formula IX.
  • the terminal carbinols of formula XIV (when n is 1 to 5) are obtained either by lithium tetrahydroaluminate reduction of the esters or acids of formula XII (e.g., when n is 1 to 5 and Mi is -CH 3 or -H) or by extending the reaction time with diborane.
  • the carboxylic acids of formulae XII and IX or pure isomers of formulae X and XI are activated for conversions to esters of formulae XII, IX, X and XI, respectively, (e.g., when n is 1 to 5 and Mi is -(C 1 -C 4 ) alkyl, phenyl or substituted phenyl) and amides of formula XXV and XVI (e.g., when n is 1 to 5 and R 5 and R 6 are as defined above) by procedures known in the art.
  • the acid chlorides are synthesized by the procedure of J. Cason, Org. Syn., Coll. Vol. 3:169 (1955).
  • the acid is reacted with, e.g., isobutylchloroformate/triethylamine in chlorocarbon solvents.
  • Other methods include those of Y. Kita, Tetrahedron Letters 25:6027 (1984); K. Saigo, Bull. Chem. Soc. Japan 50:1863 (1977); and F.H. Stodola, J. Org. Chem. 29:2490 (1964).
  • the activated acids are then reacted with the appropriate alcohol (e.g., M 1 OH) or amine (e.g., HNR 5 R 6 ) to provide the esters or amides, respectively.
  • the reaction of acid chlorides with alcohols or amines may be conducted in chlorocarbon solvents, tetrahydrofuran, or acetonitriles with an acid scavenger present (e.g., pyridine, triethylamine).
  • an acid scavenger present e.g., pyridine, triethylamine.
  • the reaction of mixed anhydrides are conducted with or without solvent, the alcohol or amine, as noted above, being used as the solvent when convenient or the above listed solvent being used as required.
  • diphenylamine borane according to the method of R. Contreras et al., Synthesis 1027 (1982), or lithium tetrahydride aluminate reduce the terminal acids or esters of formula IX (e.g., when M 1 is -H or -CH 3 ), respectively, to the unsaturated carbinols of formula XV.
  • heteroatom chains of the formula XX compound (e.g., when m is 1 or 2 and Mi is -CH 3 , -CH 2 CH 3 or -H) are elaborated by generation of the alkoxide from the formula VII compound and condensation with a halo ester (e.g., ethyl bromoacetate).
  • a halo ester e.g., ethyl bromoacetate.
  • the halomethylcyclopentapyrazole or halomethyltetrahydroindazole of formula XXI is prepared from the formula VII compound and thionyl chloride (or, alternatively, methane sulfonyl chloride).
  • the thia side chains of the formula XXII compound (e.g., when m is 1 or 2 and M 1 is -H, -CH 3 or- CH 2 CH 3 ) are Produced from the halomethylcyclopentapyrazole or halomethyltetrahydroindazole of formula XXI by condensation with a mercapto ester (e.g., methyl thioglycollate).
  • a mercapto ester e.g., methyl thioglycollate
  • terminal carbinols of formulae XXIII and XXIV are obtained either by lithium tetrahydroaluminate reduction of the esters or acids of formulae XX and XXII or by extending the reaction time of diborane reduction.
  • SRSA slow reacting substance of anaphylaxis
  • the compounds can be used for treatment of such conditions as allergic rhinitis, food allergy and urticaria as well as asthma.
  • the dosage of the compound used in treatment depends on the particular use, frequency of administration and the age or condition of the recipient.
  • the compounds can be administered intravenously, intramuscularly, topically, bucally, by aerosol, inhalation, or orally to man or other animals.
  • the dosage is about 0.01 to 10 ⁇ g/kg per minute by intravenous infusion, i.e., an i.v. drip; 0.5 to 20 mg by intravenous bolus administration one to four times per day; about 2 to 50 mg orally in single doses; 200-800 mg total daily dosage given in divided doses two or three times a day.
  • the pharmaceutically useful compounds are formulated into compositions for administration.
  • compositions of the present invention are presented for administration to humans and animals in unit dosage forms, such as tablets, capsules, pills, powders, granules, sterile parenteral solutions or suspensions, eye drops, oral solutions or suspensions, oil in water and water in oil emulsions containing suitable quantities of the compound, suppositories, aerosols and in fluid suspensions or solutions.
  • either solid or fluid unit dosage forms can be prepared.
  • the pharmaceutically useful compound of Formula XXX is mixed with conventional ingredients such as talc, magnesium stearate, dicalcium phosphate, magnesium aluminum silicate, calcium sulfate, starch, lactose, acacia, methylcellulose, and functionally similar materials as pharmaceutical diluents or carriers.
  • Capsules are prepared by mixing the compound with an inert pharmaceutical diluent and filling the mixture into a hard gelatin capsule of appropriate size.
  • Soft gelatin capsules are prepared by machine encapsulation of a slurry of the compound with an acceptable vegetable oil, light liquid petrolatum or other inert oil.
  • Fluid unit dosage forms for oral administration such as syrups, elixirs, and suspensions can be prepared.
  • the forms can be dissolved in an aqueous vehicle together with sugar, aromatic flavoring agents and preservatives to form a syrup.
  • An elixir is prepared by using a hydroalcoholic (ethanol) vehicle with suitable sweeteners such as sugar and saccharin, together with an aromatic flavoring agent.
  • Suspensions can be prepared with an aqueous vehicle with the aid of a suspending agent such as acacia, tragacanth, methylcellulose and the like.
  • a suspending agent such as acacia, tragacanth, methylcellulose and the like.
  • fluid unit dosage forms are prepared utilizing the compound and a sterile vehicle, water being preferred.
  • the pharmaceutically useful compound described herein, depending on the vehicle and concentration used, can be either suspended or dissolved in the vehicle.
  • the compound can be dissolved in water for injection and filter sterilized before filling into a suitable vial or ampoule and sealing.
  • adjuvants such as a local anesthetic, preservative and buffering agents can be dissolved in the vehicle.
  • the composition can be frozen after filling into the vial and the water removed under vacuum. The dry lyophilized powder is then sealed in the vial and an accompanying vial of water for injection is supplied to reconstitute the liquid prior to use.
  • compositions for Inhalation useful in practicing the present invention are of three basic types: (1) a powder mixture preferably micropulverized with particle size, preferably from about 2 to 5 microns; (2) an aqueous solution to be sprayed with a nebulizer; (3) an aerosol with volatile propellant in a pressurized container.
  • the powders are quite simply prepared by mixing a suitable pharmaceutically useful compound of Formula XXX with a solid base which is compatible with lung tissue, preferably lactose.
  • the powders are packaged in a device adapted to emit a measured amount of powder when inhaled through the mouth.
  • Aqueous solutions are prepared by dissolving the appropriate compound of the Formula XXX in water and adding salt to provide an isotonic solution and buffering to a pH compatible with inhalation.
  • the solutions are dispersed in a spray device or nebulizer and sprayed into the mouth while inhaling.
  • Aerosols are prepared by dissolving an appropriate pharmaceutically useful compound of Formula XXX in water or ethanol and mixing with a volatile propellant and placing in a pressurized container having a metering valve to release a predetermined amount of material.
  • the liquefied propellant employed is one which has a boiling point below 65° F at atmospheric pressure.
  • the liquefied propellant should be non-toxic.
  • suitable liquefied propellants which may be employed are the lower alkanes containing up to 5 carbon atoms, such as butane and pentane, or a lower alkyl chloride, such as methyl, ethyl or propyl chlorides.
  • liquefied propellants are the fluorinated and fluorochlorinated lower alkanes such as are sold under the trademarks "Freon” and “Genetron”. Mixtures of the above-mentioned propellants may suitably be employed.
  • propellants examples include dichlorodifluoromethane ("Freon 12"), dichlorotetrafluoroethane (“Freon 114"), trichloromonofluoromethane ("Freon 11”), dichloromonofluoromethane (“Freon 21”), monochlorodifluoromethane (“Freon 22”), trichlorotrifluoroethane ("Freon 113”), difluoroethane (“Genetron 142A”) and monochlorotrifluoromethane (“Freon 13”).
  • Cyclopentapyrazole 3-heptyl-1,4,5,6-tetrahydro-1-phenyl-; Acetic acid, [[1-(4-chlorophenyl)-1,4,5,6-tetrahydro-3-cyclopentapyrazolyl]methoxy]-; Propanoic acid, 3-[[(1,4,5,6-tetrahydro-1-phenyl-3-cyclopentapyrazolyl)methyl]thio]-; 5-Hexenoic acid, 6-[1-(4-fluorophenyl)1,4,5,6-tetrahydro-3-cyclopentapyrazolyl]-, methyl ester; 5-Hexenoic acid, 6-[1,4,5,6-tetrahydro-1-(4-methoxyphenyl)-3-cyclopentapyrazolyl]-, (E)-;
  • Propanoic acid 3-[[1,4,5,6-tetrahydro-1-[3-(trifluoromethyl)phenyl]- 3-cyclopentapyrazolyl]methoxy]-; 1H-Indazole-3-hexanol, 1-(4-bromophenyl)-4,5,6,7-tetrahydro-; 5-Hexenoic acid, 6-[1-(4-fluorophenyl)4,5,6,7-tetrahydro-1H-indazol-3-yl]-, (Z)-; 1H-Indazole-3-carboxaldehyde, 4,5,6,7-tetrahydro-1-phenyl; 4-Pentenoic acid, 5-(4,5,6,7- tetrahydro-1-phenyl-1H-indazol-3-yl)-, (E)-; Acetic acid, [[(4,5,6,7- tetrahydro-1-phenyl-1H-indazol-3-yl)
  • Hexenoic acid 6-[4,5,6,7-tetrahydro-1-[3-(trifluoromethyl)phenyl]-1H- lndazol-3-yl]-, (Z)-; 5-Hexenoic acid, 6-[4,5,6,7-tetrahydro-1-[3- (trifluoromethyl)phenyl]-1H-indazol-3-yl]-, (E)-; and 1 H- Indazole-3-pentanoic acid, 4,5,6,7-tetrahydro-1-[3-(trifluoromethyl)- phenyl]-.
  • DMF is dimethylformamide
  • DMSO is dimethylsulfoxide
  • THF is tetrahydrofuran
  • Skelly B is Skellysolve-B
  • BF 3 etherate is boronitrifluoride etherate
  • PtO 2 is platinum oxide.
  • IR infrared spectroscopy
  • NMR nuclear magnetic resonance
  • MS mass spectrum
  • UV ultraviolet spectra
  • tic thin layer chromatography
  • Dimsyl sodium was prepared from 60% sodium hydride (2.12 g, 53 mmol) in DMSO (80 ml) at 60°C during 4 hours. The solution was cooled to 18°C and 4-carboxy-butyltriphenylphosphonium bromide (11.7 g, 26.5 mmol) was added. The ylide was generated during 30 minutes and compound 1(f) (3.7 g, 13.2 mmol) was added and reacted for 30 minutes. The solution was poured into ice water (700 ml) and extracted with ether to remove neutral products. The aqueous phase was Slowly acidified with 1N hydrochloric acid and the precipitate was filtered. The filter cake was triturated with cold ethanol and crude title compound Kg) filtered (4.37 g, 91%).
  • Dimsyl sodium was prepared from 60% sodium hydride (2.65 g, 65 mmol) in DMSO (130 ml) at 60-65°C during 4 hours. The cooled solution was treated with 4-carboxybutyl-triphenylphosphonium bromide (14.4 g,
  • a solution of the 5E isoraer of Example 3 (0.31 g) in methanol (25 ml) and 1N sodium hydroxide was hydrolyzed at ambient temperature . for 18 hours. The solution was concentrated, diluted with water, acidified, and the precipitate was filtered to yield the title compound (0.36 g).
  • the analytical sample was obtained by ethanol crystallization, m.p. 163-164°C.
  • Dimsyl sodium was prepared from 60% sodium hydride and DMSO (80 ml) at 60-65°C for 4 hours. The solution was cooled to 15°C and
  • 3-carboxypropyltriphenylphosphonium bromide (11.37 g, 26.5 mmol) was added. The ylide was allowed to generate during 45 minutes. The solution was treated with the compound of Example 1(f) (3.7 g, 13.2 mmol) and reacted for 60 minutes. The reaction solution was poured into ice water (700 ml), extracted with ether, and the aqueous phase was acidified. The precipitate was filtered and the filter cake triturated with ethanol to yield the title compound (3.6 g).
  • a solution of the compound of Example 6 (1.2 g) was dissolved in methanol (250 ml), treated with 2N sodium hydroxide (35 ml) and reacted at ambient temperature for 18 hours. The solution was concentrated, diluted with water, acidified, and the precipitate was filtered to yield the title compound. Crystallization from ethanol provided pure compound, m.p. 176-177°C.
  • a solution of the 5Z-isomer of Example 3 (0.29 g) in methanol (40 ml) was treated with 1N sodium hydroxide (8 ml) and reacted at ambient temperature for 18 hours. The solution was concentrated, the residue diluted with water, and acidified with 1N hydrochloric acid. The precipitated product was filtered to yield 0.28 g of the title compound.
  • An analytical sample m.p.
  • a solution of the 5Z-isomer of Example 6 (0.80 g) was dissolved in methanol (150 ml), treated with 2N sodium hydroxide (24 ml) and reacted at ambient temperature for 18 hours. The solution was concentrated, diluted with water, acidified, and the precipitate was filtered to yield the title compound. Crystallization from ethanol gave 750 mg of pure title compound, m.p. 141-142°C as two crops.
  • Chart B A solution of crude compound of Example Kg) (0.60 mg) in ethanol (100 ml) was treated with 10% palladium on carbon (0.20 g) and reduced at 40 psi for 30 minutes. The catalyst was filtered and the solvent evaporated to yield the title compound (0.36 g). Crystallization from ethanol gave pure title compound (0.35 g), m.p. 109-110°C as two crops.
  • a solution of the compound of Example 7 (0.20 g) in glacial acetic acid (30 ml) was treated with platinum oxide (20 ml) and reduced at 40 psi for 30 minutes. The catalyst was filtered and the filtrate slowly deposited pure title compound (0.17 g), m.p. 118-119°C. An analytical sample was obtained by ethyl acetate-hexane recrystallization.
  • Chart A A solution of compound of Formula 1(c) (2.83 g) in 1:1 (vol:vol) glacial acetic acid-concentrated hydrochloric acid (60 ml) was heated at 90-95°C for 35 hours. The solution was cooled, diluted with water, and the precipitate was extracted into ethyl acetate. The extract was washed with 5% brine, dried and evaporated. Two recrystallizations gave pure title compound (0.95 g), m.p. 261°C dec.
  • the cooled suspension of hydrochloride salt was treated with sodium nitrite (20.7 g) at -5°C at a rate which maintained the reaction temperature at -2°C.
  • the diazonium salt solution was added to a solution of ethyl acetoacetate (39 g, 0.3 mmol) in ethanol (225 ml) and ice water (1.5 L) containing sodium acetate (75 g, 0.9 mmol). The mixture thickened and sufficient water was added to permit agitation for 3.5 hours.
  • the crude acids were esterif ied with excess ethereal diazoraethane and the crude esters (16.0 g) were fractionated on silica gel (1 kg) using 9:1 Skelly B-ethyl acetate (250 ml fractions). After a forerun, the Z-isomer was collected in fractions 4-16 and crystallized from ethanol to yield pure compound, 1.98 g, m.p. 76-77°C. Fractions 28-49 provide pure E-isomer (2.18 g, m.p. 114-115°C). The intermediate fractions provided 0.2 g of mixed products.
  • Example 13(g) A suspension of the E-isomer of Example 13(g) (0.5 g) in methanol (50 ml) and 2N sodium hydroxide was warmed at 45°C for 1.5 hours. The solution was then reacted at ambient temperature for 18 hours. The solution was diluted with water, acidified, and the precipitate filtered to yield the title compound. Crystallization from ethanol gave pure title compound (0.32 g), m.p. 232-233°C.
  • pyridine 25 ml
  • piperidine 0.1 ml
  • malonic acid 2.08 g, 20 mmol
  • the solution was concentrated in vacuo, diluted with water (200 ml) and acidified with hydrochloric acid.
  • a suspension of the Z-isomer of Example 13(g) (0.50 g) in methanol (50 ml) was treated with 2N sodium hydroxide and reacted for 18 hours. The solution was diluted with water, acidified and the precipitate was extracted into ethyl acetate. Evaporation of solvent gave the title compound. Crystallization from ethanol gave pure title compound (0.33 g), m.p. 163-164°C.
  • Chart A A solution of compound 13(c) (1.0 g) in 25% polyphosphoric acid in acetic acid (10 ml) was heated at 130°C for 3 hours. The solution was diluted with ice water and the precipitate filtered to yield pure title compound (0.58 g). Additional material was recovered by the filtrate by partial neutralization with solid sodium acetate. Crystallization from ethanol provided an analytical sample of title compound, m.p. 180-181°C.
  • Example 23(b) compound (12.8g, 35 mmol) in acetic acid (40 ml) and 1N hydrochloric acid (40 ml) was heated at 90-95°C for 20 minutes. The solution was cooled, the crystalline precipitate was filtered and washed with water to yield the title compound, 9.4g. Recrystallization from ethanol provided the analytical sample, m.p. 122.5- 123°C
  • Lithium aluminum hydride (2.20 g, 58 mmol) in THF (475 ml) was treated with the compound of Example 23(c) (9.5 g, 32 mmol) and reacted for 30 minutes.
  • the suspension was treated with 10% aqueous THF (10 ml), 15% sodium hydroxide (3 ml) and water (25 ml), filtered, and the filter cake was washed with ethyl acetate.
  • the combined filtrates were evaporated to yield the title compound (7.30 g), m.p. 149-150°C.
  • An analytical sample (m.p. 149-150°C) was obtained from ethyl acetate-hexane solution.
  • Example 23(e) (6.5 g, 26.4 mmol) added. Reaction was allowed to proceed for 24 hours, the solution poured into ice water and the precipitate filtered. The alkaline filtrate and water washes were extracted with ether and the aqueous phase was acidified. The precipitate was filtered to yield the title compound (9.22 g), m.p. 146-147°C. Crystallization from ethanol gave the title compound as a 1:1 E:Z mixture (7.47 g). IR (mull): 3200-2400, 1700, 1590, 1545, 1490, 1405, 1315, 1285,
  • methyl esters were dissolved in ethyl acetate (100 ml), treated with platinum oxide (0.16 g) and hydrogenated at 40 psi for one hour.
  • a suspension of 60% sodium hydride (0.26 g, 5.5 mmol) in THF (25 ml) was treated with the compound of Example 23(d) (1.31 g, 5 mmol) and heated at reflux for 3 hours. The mixture was treated with ethyl bromoacetate and reacted for 48 hours. The mixture was treated with
  • the crude product was dissolved in methanol (75 ml), treated with 1N sodium hydroxide (30 ml), heated at 95°C for 5 minutes, and concentrated in vacuo.
  • the concentrate was diluted with water and extracted with ethyl acetate.
  • the alkaline layer was acidified and the precipitate extracted into ethyl acetate. Evaporation of solvent gave pure title compound (0.91 g), m.p. 122-123°C after ether trituration.
  • a solution of the compound of Example 28(f) (1.38 g, 44 mmol) in methanol (30 ml) and ethyl acetate (30 ml) at 0°C was treated with excess ethereal diazomethane. Excess reagent was quenched with acetic acid, the solution was washed with 5$ sodium bicarbonate solutions, dried and evaporated. The residue deposited the title compound (1.43 g), m.p. 67-68°C, from hexane solution.
  • a solution of the compound of Example 30 (1.3 g, 4 mmol) in methanol (120 ml) was treated with 1N sodium hydroxide (40 ml) and reacted at ambient temperature for 7 hours. The solution was concentrated, cooled, and acidified. The precipitate was extracted into ethyl acetate, dried and evaporated. The residue was crystallized from ethanol to yield pure title compound (1.03 g), m.p. 64-67°C.
  • Lithium tetrahydridoalurainate (0.345 g, 9.1 mmol) in THF (75 ml) was treated with the compound of Example 31 (1.0 g, 3.1 mmol) and the mixture was heated at 60°C for 2 hours. Excess reagent was quenched, the mixture filtered and the combined filtrate and ethyl acetate washes were evaporated to a colorless oil (0.76 g). Polar impurities were removed on silica gel (40 g) with 1:1 ethyl acetate-Skelly B eluent to provide title compound (0.42 g)
  • Dimsyl sodium was prepared from 60% sodium hydride (1.28 g, 32 mmol) in dimethylsulfoxide (50 ml) at 60-65°C during 3 hours. The solution was cooled and treated with 4-carboxybutyltriphenylphosphonium bromide (7.0 g, 16 mmol) and reacted at ambient temperature for 30 minutes. The solution was treated with the compound of Example 34(e) (1.7 g, 8 mmol) and reacted for 30 minutes. The solution was diluted with 300 ml of ice water and extracted with ethyl acetate. The aqueous layer was acidified and the precipitate extracted into ethyl acetate.
  • Dimsyl sodium was prepared from 60% sodium hydride (1.3 g, 32 mmol) in DMSO (65 ml) at 65°C. The solution was cooled to insipient freezing and 3-carboxypropyltriphenylphosphonium bromide (6.8 g, 16 mmol) added.
  • Dtmsyl sodium was prepared from 60$ sodium hydride (1.3 g, 32 mmol) in DMSO (50 ml) at 60-65°C. Hexyl triphenyl phosphonium bromide (12.8 g, 30 mmol) was added and reacted for 30 minutes. The aldehyde of Example 34(e) (2.5 g, 11.8 mmol) was added, reacted at ambient temperature for
  • IR 1600, 1565, 1510, 1465, 1445, 1385, 1330, 1300, 1270, 1165, 1120, 1075, 1055, 1030, 970, 900 and 760 cm -1 .
  • a solution of the compound of Example 37 (0.41 g) in ethyl acetate (60 ml) was treated with PtO 2 (0.25 g) and hydrogenated at 40 psi for 3 hours. Catalyst was filtered to provide impure title compound (0.22 g). Purification on silica gel with 1% ethyl acetate in Skelly B gave pure title compound (0.17 g) as an oil.
  • IR 1600, 1565, 1510, 1500 (sh), 1470, 1390, 1300, 1120, 1090, 1065, 1050, 1025 and 755 cm -1 .
  • Dimsyl sodium was prepared with 60$ sodium hydrode (2.56 g, 64 mmol) in DMSO (128 ml) at 60-65°C. The solution was cooled, treated with 6- carboxyhexyltriphenylphosphonium bromide (15.07 g, 32 mmol) and reacted for 45 minutes. The ylide solution was treated with the compound of
  • Example 34(e) (3.4 g, 16 mmol) and reacted for 18 hours.
  • the solution was diluted with water, the alkaline mixture extracted with ether, and the aqueous phase was acidified.
  • the crude precipitate was extracted into ether, washed with 5% brine solution, dried and evaporated.
  • the residual oil (12.6 g) was purified on CC-4 silica gel (700 g).
  • the first eluted (1:9 ethyl acetate-Skelly B) product gave the Z-isomer title compound (3.6 g), the intermediate fraction gave mixed products (1.1 g), and the final eluate gave pure E-isomer title compound (0.60 g).
  • Chart E A solution of 1-phenyl-1,4,5,6-tetrahydro-3-cyclopentapyrazolemethanol (2.14 g, 10 mmol) in THF (40 ml) was cooled to -10°C and treated with 1.6M n-butyl lithium (6.2 ml, 10 mmol) using bipyridyl indicator. After 20 minutes, ethyl bromoacetate (1.9 g, 1.26 ml, 11.4 mmol) was added, reacted at -20°C for 45 minutes, then at ambient temperature for 18 hours. The solution was poured into ice water, acidified, and the products extracted into ethyl acetate.
  • Chart B A solution of the compound of Example 34(f) (0.25 g, 0.8 mmol) in chloroform (50 ml) was treated with platinum oxide (0.10 g) and reduced at 40 psi of hydrogen for one hour. The catalyst was filtered, the filtrate evaporated to a non-crystalline residue. Crystallization from either acetoni trite or 3:1 methanol-water gave the title compound, m.p.95- 96°C.
  • a solution of the crude esters produced in Example 36 (1.1 g, 3.9 mmol) in ethyl acetate (100 ml) was treated with platinum oxide (0.35 g) and reduced at 40 psi hydrogen pressure during 3 hours.
  • Example 51(b) A solution of the compound of Example 51(b) (5.0 g, 20.5 mmol) in toluene (300 ml) was treated with activated manganese dioxide (15 g) and azeotropically distilled for 4 hours. The cooled solution was filtered and evaporated to yield crude title compound (3.09 g). Filtration through silica gel removed polar contaminants and provided pure title compound (2.16 g) as an oil.
  • Dimsylsodium was prepared from 60% sodium hydride (1.40 g, 3.2 mmol) in DMSO (70 ml) at 60-65°C for 3.5 hours. The cooled solution was treated with 4-carboxybutyltriphenylphosphonium bromide (7.84 g, 17.7 mmol) and reacted at room temperature for 30 minutes. The solution was treated with the compound of Example 51(c) (2.0 g, 8.8 mmol) and reacted for 18 hours. The reaction solution was poured into ice water and neutral products were extracted into methylene chloride. The aqueous phase was acidified and the oily precipitate was extracted into 1:1 ether-ethyl acetate.
  • a suspension of 4-bromoaniline (68.8 g) in water (32 ml) was treated with concentrated hydrochloric acid (100 ml) and heated for 30 minutes.
  • the suspension was treated with ice (400 ml) and maintained at 0°C while a solution of sodium nitrite (27.6 g) in water (50 ml) was added.
  • the diazoniura salt solution was added in one portion to a solution of ethyl acetoacetate (52 g) in ethanol (300 ml) and 3 ⁇ dium acetate (100 g) in ice water (1L). The suspension was agitated for 3 hours at 0°C and product was filtered. Crystallization of the precipitate from ethanol provided 107.7 g of the title compound, m.p. 102-104°C.
  • IR film: 1700, 1590, 1580, 1530, 1480, 1465 (sh), 1450 (sh), 1420, 1390, 1365, 1310, 1260, 1150, 1025, 1015 (sh), 995, 935, 835 and 775 cm -1 .
  • Example 54 5-[1-(3-Trifluoromethylphenyl)-4,5,6,7-tetrahydro-1Hindazol-3-yl]-4Z-pentenoic acid and -4E-pentenoic acid
  • R 1 3-trifluoromethylphenyl
  • Dimsyl sodium was generated from 60% sodium hydride (2.17 g) in DMSO (110 ml) at 65°C during 3 hours. The solution was cooled and 4-carboxybutyltriphenylphosphonium bromide (12.03 g) was added and reacted for 30 minutes. The ylide solution was treated with the compound of Example 56(d) (3.07 g) and reacted for 2 hours. The solution was poured into ice water and neutral products removed by ether extraction. The aqueous phase was acidified and the precipitate was extracted into ethyl acetate. The extract was washed, dried and evaporated to a viscous residue (3.25 g).
  • Dimsyl sodium was generated from 60$ sodium hydride (1.3g, 32 mmol) in DMSO (60 ml) at 60 °C. The solution was treated with 3-carboxypropyltriphenylphosphonium bromide (6.8 g, 16 mmol) and reacted for 30 minutes at ambient temperature.
  • the aldehyde prepared in Example 56(d) (1.8 g,
  • R 1 phenyl
  • Dimsyl sodium was generated from 60% sodium hydride (3.52 g) in DMSO (200 ml) at 65°C during 4 hours. The cooled solution was treated with 4-carboxybutyltriphenylphosphonium bromide and reacted for one hour.
  • the ylide solution was treated with the compound of Example 62(e) (6.0 g) and heated for an hour.
  • the reaction solution was diluted with water and extracted with ether.
  • the aqueous phase was acidified and the semi-solid precipitate was extracted into ethyl acetate.
  • 'Drying and evaporation of solvent gave a residue (15.6 g) of crude hexenoic acid and Wittig reaction by-products. Crystallization of the residue from methanol gave the Z-isomer (2.2 g) which was further purified by crystallization from ethanol to yield pure title compound Z-isomer (1.68 g, m.p. 178-180°C).
  • a solution of the compound of Example 63 (0.20 g) in methanol (20 ml) was treated with N sodium hydroxide (7.5 ml) and heated at reflux temperature for 30 minutes. The cooled solution was acidified and the precipitate was crystallized from acetonitrile to yield pure title compound (0.15 g), m.p. 119-121°C.
  • Lithium tetrahydride aluminate (1.55 g, 80 mmol) in THF (600 ml) was treated in portions with the compound of Example 67(a) (11.67 g, 40 mmol) and reacted for one hour.
  • the suspension was quenched by dropwise addition of water (10 ml) in THF, 15% sodium hydroxide (20 ml) and finally water.
  • the suspension was filtered, the filter cake washed with THF and the filtrate evaporated to dryness. Recrystallization of the residue from ethyl acetate-hexane solution gave pure title compound, 8.75 g, m.p. 117-118°C.
  • the solution was treated with 4-carboxybutyltriphenylphosphonium bromide (5.40 g, 12.1 mmol) at 5°C and reacted for 1.25 hours.
  • the ylide solution was treated with the compound of Example 67(c) (1.46 g, 6.09 mmol) and reacted at 25 °C for one hour.
  • the solution was poured into ice water, neutral products extracted into ethyl acetate, and the aqueous phase was acidified. The precipitated acids were extracted into ethyl acetate, washed, and dried to yield crude title compounds.
  • R 1 4-fluorophenyl
  • a solution of the Z-isomer of Example 67(d) (0.50 g) in ethanol (100 ml) was treated with 10$ palladium on carbon (0.20 g) and hydrogenated at 40 psi for one hour. The mixture was filtered and the filtrate evaporated to yield the title compound (0.43 g). Recrystallization from acetonitrile solution gave an analytical sample, m.p. 95-96°C.
  • a solution of the mixed ethyl and methyl esters of 1-(4-chlorophenyl)-4,5,6,7-tetrahydro-1H-indazole-3-carboxylic acid (5.5g) in methanol (800 ml) was treated with 2N sodium hydroxide (95 ml) and reacted at ambient temperature. Only the thin layer chromatography more polar methyl ester remained. The solution was heated at reflux temperature for 60 minutes, cooled, concentrated, and acidified.
  • a solution of the compound of Example 73 (0.75 g) in methanol (15 ml) was treated with N sodium hydroxide (6 ml) and reacted at room temperature for 15 minutes. The solution was concentrated in vacuo, diluted with water, and acidified. The precipitate was filtered to yield the title compound (0.58 g).
  • An analytical sample (m.p. 185-186°C) was obtained from methanol-hexane solution.
  • a solution of the methyl and ethyl esters of 1-(2,4-dichlorophenyl)4,5,6,7-tetrahydro-1H-indazole-3-carboxylic acid (5g, 1.8g) in methanol
  • R 1 4-bromophenyl
  • Example 53(d) A solution of the compound prepared in Example 53(d) (2.0 g) in methanol (60 ml) was treated with 3N sodium hydroxide (10 ml) and reacted at ambient temperature for 18 hours. The solution was concentrated, acidified and the precipitate (1.63 g) was crystallized from 80% ethanol to yield pure title compound (1.46 g), m.p. 183-184°C.
  • a solution of 6-[3-(trifluoromethyl)phenyl]-1,4,5,6-tetrahydro-3- cyclopentapyrazolyl]-(Z)-5-hexenoic acid methyl ester (0.21 g) in methylene chloride (10 ml) is treated with m-chloroperoxybenzoic acid and re acted at room temperature for 18 hours.
  • a suspension of 1-phenyl-1,4,5,6-tetrahydro-3-cyclopentapyrazole carboxaldehyde (110 g) in toluene (1 L) is treated with 2, 2-dimethyl propane diol (59.3 g), toluenesulfonic acid (600 mg), and azeotropically distilled for 2 hours.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Cette invention concerne des compositons novatrices et leurs applications thérapeutiques, en particulier des composés novateurs de cyclopentapyrazole et de tétrahydroindazole ayant la formule (XXX) et leur utilisation comme agents anti-allergiques, anti-inflammatoires ou intermédiaires.
PCT/US1986/001233 1985-06-14 1986-06-03 Composes de cyclopentapyrazole et de tetrahydroindazole WO1986007357A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US74534385A 1985-06-14 1985-06-14
US745,343 1985-06-14

Publications (2)

Publication Number Publication Date
WO1986007357A2 WO1986007357A2 (fr) 1986-12-18
WO1986007357A3 true WO1986007357A3 (fr) 1987-04-23

Family

ID=24996305

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1986/001233 WO1986007357A2 (fr) 1985-06-14 1986-06-03 Composes de cyclopentapyrazole et de tetrahydroindazole

Country Status (3)

Country Link
US (1) US4851425A (fr)
EP (1) EP0226624A1 (fr)
WO (1) WO1986007357A2 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5134155A (en) * 1991-08-08 1992-07-28 Ortho Pharmaceutical Corporation Tetrahydroindazole, tetrahydrocyclopentapyrazole, and hexahydrocycloheptapyrazole compounds and their use as HMG-coA reductase inhibitors
MX9606331A (es) * 1994-06-14 1997-03-29 Dainippon Pharmaceutical Co Nuevos compuestos, procesos para la preparacion de los mismos y agentes antitumor.
CN1956964B (zh) * 2004-03-24 2011-06-15 詹森药业有限公司 四氢-吲唑***素调节剂
RU2459808C1 (ru) * 2011-02-25 2012-08-27 Государственное образовательное учреждение высшего профессионального образования "Пермский государственный университет" 3-(1-нафтилметил)-4,5,6,7-тетрагидроиндазола гидрохлорид, средство, обладающее противомикробными свойствами

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS50157363A (fr) * 1974-06-06 1975-12-19
SU553246A1 (ru) * 1975-10-07 1977-04-05 Московский Ордена Ленина И Ордена Трудового Красного Знамени Химикотехнологический Институт Им.Д.И.Менделеева Способ получени индазол-3-альдегида

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1948793A1 (de) * 1969-09-26 1971-04-01 Rhein Chemie Rheinau Gmbh Verfahren zur Herstellung von 4,5,6,7-Tetrahydroindazolen
FR2315924A1 (fr) * 1975-07-03 1977-01-28 Enzypha Nouveaux polymethylene-4,5 pyrazoles, leur procede de preparation et leur application en therapeutique

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS50157363A (fr) * 1974-06-06 1975-12-19
SU553246A1 (ru) * 1975-10-07 1977-04-05 Московский Ордена Ленина И Ордена Трудового Красного Знамени Химикотехнологический Институт Им.Д.И.Менделеева Способ получени индазол-3-альдегида

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CHEMICAL ABSTRACTS, Volume 85, No. 17, 25 October 1976, (Columbus, Ohio, US), s ee page 644, Abstract 123913n, & JP, A, 75157363 (Sumitomo Chemical Co., Ltd) 19 decembre 1975 *
CHEMICAL ABSTRACTS, Volume 87, No. 23, 5 December 1977, (Columbus, Ohio, US), see page 613, Abstract 184511t, & SU, A, 553 246 (Mendeleev, D.I., Chemical-Technological Institute, Moscow) 5 avril 1977 *

Also Published As

Publication number Publication date
EP0226624A1 (fr) 1987-07-01
WO1986007357A2 (fr) 1986-12-18
US4851425A (en) 1989-07-25

Similar Documents

Publication Publication Date Title
DK170202B1 (da) 1,5-diaryl-3-substituerede pyrazolforbindelser, fremgangsmåde til fremstilling deraf og farmaceutiske præparater indeholdende forbindelserne
FI69451C (fi) Foerfarande foer framstaellning av antiinflammatoriska 4,5-diaryl-2-nitroimidazoler
US4402968A (en) Antifungal benzofuranyl imidazole compounds
KR100191774B1 (ko) 피라졸로[1,5-알파] 피리미딘 유도체 및 이것을 함유하는 항염증제
JPH10504836A (ja) オルト置換芳香族エーテル化合物及び鎮痛のための薬剤組成物中へのこれらの使用
JPH01316363A (ja) ピペラジン誘導体およびその塩
NZ229761A (en) Substituted thiazole derivatives for use as inhibitors of enzyme 5-lipoxygenase; pharmaceutical compositions and preparatory processes
US5110831A (en) Vinylogous hydroxamic acids and derivatives thereof as 5-lipoxygenase inhibitors
US5242940A (en) Pharmacologically active N-1 and C-5 heterocyclic pyrazoles and method for synthesizing the same
JPH0687847A (ja) ロイコトリエン生合成の阻害剤としてのヘテロアリールナフタレン
US4442115A (en) 2'Hydroxy tetrazole-5-carboxanilides and anti-allergic use thereof
US4595699A (en) Immune system regulation using novel phenylalkanoic acid derivative
HU190573B (en) Process for producing new beta-carboline derivatives and pharmaceutical compositions cintaining them
US3940434A (en) Dicarboxylic acids and derivatives
JPH035455A (ja) 置換ピロリジン化合物および医薬組成物
US4851425A (en) Cyclopentapyrazole and tetrahydroindazole compounds and their use as anti-inflammatory and anti-allergic agents
US4766138A (en) Use of 4-(isoxazolyl)-thiazole-2-oxamic acid derivatives
US3625970A (en) 1-(disubstituted phenyl or benzyl)-1h-indazol-3-yloxyacetic acid
IE870217L (en) Benzothiophene derivatives
US4254056A (en) 2-Aminomethyl phenol derivative and process for preparing thereof
US4156730A (en) Pharmaceutically active compounds, preparation thereof, intermediates useful in such preparation and compositions containing the compounds
US4906658A (en) Fluoro-sulfones
JPH02275878A (ja) ピラゾロピリジン系メバロノラクトン類
EP0314464B1 (fr) Dérivés de thiophène
JPH0474354B2 (fr)

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): JP US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE FR GB IT LU NL SE

AK Designated states

Kind code of ref document: A3

Designated state(s): JP US

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH DE FR GB IT LU NL SE